Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea · Delayed Price · Currency is KRW 168,900
-1,400 (-0.82%)
At close: Jan 30, 2026
Daewoong Pharmaceutical Revenue
Daewoong Pharmaceutical had revenue of 411.83B KRW in the quarter ending September 30, 2025, with 14.88% growth. This brings the company's revenue in the last twelve months to 1.54T, up 8.83% year-over-year. In the year 2024, Daewoong Pharmaceutical had annual revenue of 1.42T with 3.44% growth.
Revenue (ttm)
1.54T
Revenue Growth
+8.83%
P/S Ratio
1.26
Revenue / Employee
937.74M
Employees
1,644
Market Cap
1.94T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.42T | 47.35B | 3.44% |
| Dec 31, 2023 | 1.38T | 95.24B | 7.44% |
| Dec 31, 2022 | 1.28T | 127.12B | 11.03% |
| Dec 31, 2021 | 1.15T | 97.55B | 9.24% |
| Dec 31, 2020 | 1.06T | -58.00B | -5.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daewoong | 2.06T |
| GC Biopharma | 1.93T |
| Chong Kun Dang Pharmaceutical | 1.68T |
| Dong-A Socio Holdings | 1.40T |
| Boryung | 1.03T |
| DongKook Pharmaceutical | 894.93B |
| JW Pharmaceutical | 764.21B |
| Ildong Pharmaceutical | 575.66B |
Daewoong Pharmaceutical News
- 6 weeks ago - AEON Biopharma announces execution of exchange agreement with Daewoong Pharmaceutical - Seeking Alpha
- 10 months ago - Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis - Business Upturn